Trial record 1 of 1 for:    NCT00402714
Previous Study | Return to List | Next Study

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00402714
Recruitment Status : Completed
First Posted : November 22, 2006
Results First Posted : January 18, 2017
Last Update Posted : January 18, 2017
Hospira, now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
Yale University

Brief Summary:
This is a study to explore the use of a reduced intensity transplant conditioning regimen. A conditioning regimen is the treatment that is given to prepare a body for the new bone marrow that will be received from a donor. Reduced intensity conditioning uses lower doses of chemotherapy than conventional conditioning regimens. The use of lower doses of drugs and radiation cause fewer side effects. Reduced intensity regimens have been offered to older patients or patients at increased risk for transplant-related side effects and have been shown to be safe and effective. Reduced intensity conditioning regimens are now considered for many patients who are undergoing transplant.

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Procedure: extracorporeal photopheresis Drug: Pentostatin Radiation: Total Body Irradiation Phase 2

Detailed Description:

One of the complications of allogeneic stem cell transplant (ASCT) is graft versus host disease (GVHD). This is when the donor cells that are infused attack the body organs. This can cause serious illness and even death. The chance of getting serious life threatening GVHD with conventional transplant conditioning regimens is 25-50% depending on whether the donor bone marrow is from a family member or an unrelated person. The reduced intensity conditioning regimen used in this study involves a drug called pentostatin as well as a reduced dose of radiation and a treatment called photopheresis. This regimen has been successfully used in 106 patients. The incidence of serious GVHD in those patients was much less than expected: 8% for patients getting bone marrow from a family member and 23% for those getting bone marrow from an unrelated person. The pentostatin and radiation parts of this reduced intensity conditioning regimen are similar to other types of reduced intensity regimens, which use drugs similar to pentostatin. The unique part of this regimen compared to others is the use of extracorporeal photopheresis (ECP).

While ECP has been used in 106 patients as part of a reduced intensity conditioning regimen, it is unknown whether adding ECP to pentostatin and radiation is what caused the reduced rate of GVHD that was seen in the previous study that was done. The use of ECP as part of a conditioning regimen is investigational. ECP is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma, but is not approved by the FDA for use prior to ASCT.

Because it is not known whether the use of ECP in the reduced intensity conditioning regimen was what caused the low incidence of GVHD, this research study will look at differences in getting GVHD based on whether you receive ECP. Half the patients in this research study will receive ECP as part of their reduced intensity-conditioning regimen and the other half will not. Patients will be randomized (50% chance you will receive ECP and 50% chance you will not). Both groups will receive pentostatin and reduced dose total body irradiation. The primary purpose of this research study is to look at the chance of developing serious GVHD within the first 100 days after transplant within each group.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Study Start Date : July 2006
Actual Primary Completion Date : July 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Pentostatin
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Extracorporeal photopheresis, pentostatin and total body irradiation
Procedure: extracorporeal photopheresis
Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
Other Names:
  • UVAR® XTS Photopheresis System
  • 8-methoxypsoralen
  • methoxsalen
Drug: Pentostatin
pentostatin 8mg/m2 over 48 hours by continuous infusion
Other Names:
  • DCF
  • 2-Deoxycoformycin
  • Nipent
Radiation: Total Body Irradiation
600cGy TBI in 3 200cGy TBI fractions
Active Comparator: 2
Pentostatin and total body irradiation
Drug: Pentostatin
pentostatin 8mg/m2 over 48 hours by continuous infusion
Other Names:
  • DCF
  • 2-Deoxycoformycin
  • Nipent
Radiation: Total Body Irradiation
600cGy TBI in 3 200cGy TBI fractions

Primary Outcome Measures :
  1. Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis [ Time Frame: Day +100 following allogeneic stem cell transplant ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 2 years following stem cell transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must give informed consent to receive study treatment.
  • Availability of a suitable 5/6 (Class I mismatch) or 6/6 HLA-matched related or 10 or 10 matched unrelated donor.
  • Adequate cardiac function with an ejection fraction ≥ 35% by echocardiography or nuclear cardiography within three months of transplantation
  • Adequate pulmonary function with corrected DLCO ≥ 40% by pulmonary function testing within the past three months of transplantation
  • Adequate renal function with creatinine clearance ≥ 30 ml/min. as calculated by the Cockroft and Gault method.
  • Adequate hepatic function with AST, ALT, alkaline phosphatase, and total bilirubin no more than 3 x ULN unless related to neoplastic disease.
  • Adequate vascular access, either by pheresis flow catheter or peripheral vein intravenous catheter, to perform ECP, should the patient be randomized to ECP.
  • Patients with prior autologous stem cell transplantation are eligible.
  • Age 18 to 75 years.
  • Life expectancy of greater than 3 months.
  • ECOG performance status of 0, 1, or 2.
  • Platelet counts ≥ 20,000/microliter, with or without transfusion support, at the time of ECP, should the patient be randomized to ECP.
  • Weight ≥ 40 kg.
  • Systolic blood pressure ≥ 90 mmHg on the day randomization occurs
  • Negative pregnancy test. The effects of ECP on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Able to receive 600 cGy of total body irradiation. If patient previously treated by TBI then must be able to receive 400cGY of total body irradiation.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Hypersensitivity or allergy to 8-methoxypsoralen.
  • Prior allogeneic stem cell transplantation
  • HLA-DR mismatch or no worse than one antigen-mismatched unrelated donor.
  • Patients with acute leukemia or acute lymphocytic leukemia with > 5% circulating blasts in peripheral blood or > 5% blasts in bone marrow aspirate and biopsy at the time of registration
  • Patients with chemorefractory non-Hodgkin's lymphoma or Hodgkin's disease or multiple myeloma
  • Diagnosis of myelofibrosis
  • Patients known to be positive for antibodies to HIC or have evidence for active HIC viral replication.
  • Participation in another clinical trial for prevention of GVHD.
  • Patient is pregnant or lactating.
  • Lack adequate vascular access for ECP.
  • Systolic blood pressure < 90 mmHg at the time of randomization, should the patient be randomized to ECP.
  • Evidence of active, ongoing infection.
  • Unwilling to comply with all study procedures.
  • Unable or unwilling to give signed informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00402714

United States, Connecticut
Yale Comprehensive Cancer Center at Yale University School of Medicine
New Haven, Connecticut, United States, 06520
United States, Massachusetts
Tufts-New England Medical Center
Boston, Massachusetts, United States, 02111
United States, Texas
Methodist Hospital - Texas Transplant Institute
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Yale University
Hospira, now a wholly owned subsidiary of Pfizer
Principal Investigator: Francine Foss, M.D. Yale University

Responsible Party: Yale University Identifier: NCT00402714     History of Changes
Other Study ID Numbers: 0508000433
First Posted: November 22, 2006    Key Record Dates
Results First Posted: January 18, 2017
Last Update Posted: January 18, 2017
Last Verified: November 2016

Keywords provided by Yale University:
Allogeneic Stem Cell Transplant

Additional relevant MeSH terms:
Antineoplastic Agents
Adenosine Deaminase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Photosensitizing Agents
Dermatologic Agents